WO2007118963A3 - Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations - Google Patents

Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations Download PDF

Info

Publication number
WO2007118963A3
WO2007118963A3 PCT/FR2007/000512 FR2007000512W WO2007118963A3 WO 2007118963 A3 WO2007118963 A3 WO 2007118963A3 FR 2007000512 W FR2007000512 W FR 2007000512W WO 2007118963 A3 WO2007118963 A3 WO 2007118963A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenethyl
substituted
preparation
benzamide derivatives
derivatives
Prior art date
Application number
PCT/FR2007/000512
Other languages
English (en)
Other versions
WO2007118963A2 (fr
Inventor
Christophe Masson
Karine Bertrand
Original Assignee
Genfit
Christophe Masson
Karine Bertrand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit, Christophe Masson, Karine Bertrand filed Critical Genfit
Publication of WO2007118963A2 publication Critical patent/WO2007118963A2/fr
Publication of WO2007118963A3 publication Critical patent/WO2007118963A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

La présente invention concerne des dérivés du type N-(phénéthyl)benzamide poly-substitués, les compositions pharmaceutiques les comprenant ainsi que leurs applications thérapeutiques, notamment dans les domaines de la santé humaine et animale. La présente invention a également trait à un procédé de préparation de ces dérivés.
PCT/FR2007/000512 2006-03-24 2007-03-23 Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations WO2007118963A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0602587 2006-03-24
FR0602587A FR2898894B1 (fr) 2006-03-24 2006-03-24 Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations

Publications (2)

Publication Number Publication Date
WO2007118963A2 WO2007118963A2 (fr) 2007-10-25
WO2007118963A3 true WO2007118963A3 (fr) 2007-12-21

Family

ID=37440693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000512 WO2007118963A2 (fr) 2006-03-24 2007-03-23 Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations

Country Status (2)

Country Link
FR (1) FR2898894B1 (fr)
WO (1) WO2007118963A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2154739A1 (fr) * 1971-10-01 1973-05-11 Boehringer Mannheim Gmbh
EP0305890A2 (fr) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Utilisation du bézafibrate pour le traitement du diabète
WO1993000337A1 (fr) * 1991-06-21 1993-01-07 Dr. Karl Thomae Gmbh Acides (s)(+)-2-ethoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoique
US6528525B1 (en) * 1997-10-02 2003-03-04 Sankyo Company, Limited Amidocarboxylic acid derivatives
WO2003074495A1 (fr) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Activateurs de hppars
WO2006035157A2 (fr) * 2004-09-27 2006-04-06 Genfit Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2154739A1 (fr) * 1971-10-01 1973-05-11 Boehringer Mannheim Gmbh
EP0305890A2 (fr) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Utilisation du bézafibrate pour le traitement du diabète
WO1993000337A1 (fr) * 1991-06-21 1993-01-07 Dr. Karl Thomae Gmbh Acides (s)(+)-2-ethoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoique
US6528525B1 (en) * 1997-10-02 2003-03-04 Sankyo Company, Limited Amidocarboxylic acid derivatives
WO2003074495A1 (fr) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Activateurs de hppars
WO2006035157A2 (fr) * 2004-09-27 2006-04-06 Genfit Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARBARA S. GROSS ET AL.: "Peroxisome Proliferator-Activated Receptor beta/delta: A novel target for the reduction of atherosclerosis.", DRUG DISCOVERY TODAY:THERAPEUTIC STRATEGIES, vol. 2, no. 3, 2005, Elsevier Ltd., pages 237 - 243, XP002409544 *
HIROYUKI MIYACHI: "Analysis of patent applications relating to peroxisome proliferator-activated receptor(PPAR) ligands in 2004", EXPERT OPINION THERAPEUTIC PATENTS, vol. 15, no. 11, 2005, Ashley Publications, GB, pages 1521 - 1530, XP002409543 *
WEIGAND ET AL: "Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 20, 15 October 2005 (2005-10-15), pages 4619 - 4623, XP005064664, ISSN: 0960-894X *
YANFANG LIU ET AL.: "Ligands to peroxisome proliferator-activated receptors as therapeutic options for metabolic syndrome.", DRUG DISCOVERY TODAY:THERAPEUTIC STRATEGISE, vol. 2, no. 2, 2005, Elsevier Ltd., pages 165 - 169, XP002409545 *

Also Published As

Publication number Publication date
FR2898894A1 (fr) 2007-09-28
FR2898894B1 (fr) 2008-06-06
WO2007118963A2 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2008012470A3 (fr) Derives d'imidazolones substitues, preparation et utilisations
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2007062078A3 (fr) Composes modulant l'activite thrombopoietine et procedes correspondants
WO2006059234A3 (fr) Amides bicycliques comme inhibiteurs de kinases
IL195030A (en) IV dpp inhibitor assemblies
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2006035157A3 (fr) Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IL178425A0 (en) Carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
WO2008087366A3 (fr) Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2008087365A3 (fr) Derives de 1,3-diphenylpropane substitues, preparations et utilisations
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2007012479A3 (fr) Composes
WO2009032843A3 (fr) Aminoalcools substitués
WO2009053628A3 (fr) Nouveaux composes, préparation et utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731195

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07731195

Country of ref document: EP

Kind code of ref document: A2